This is a randomized, single-center, single-blind, placebo-controlled, dose-escalation Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of multiple intravenous (IV) infusions of KINE-101 in healthy adult volunteers. The study includes three sequential cohorts with a total of 24 subjects (8 subjects per cohort; 6 assigned to KINE-101 and 2 to placebo). Subjects in the treatment groups receive KINE-101 once daily for 7 consecutive days at doses corresponding to their assigned cohort (Cohort 1: 120 mg, Cohort 2: 240 mg, Cohort 3: 360 mg). Subjects in the placebo group receive 0.9% saline under identical conditions. All subjects are admitted on Day -1, receive daily dosing from Day 1 through Day 7, and are discharged on Day 9 after completion of safety monitoring. Follow-up visits are conducted on Days 14, 21, 28, and 35. Dose escalation proceeds sequentially from the lowest-dose cohort (Cohort 1) to the highest-dose cohort (Cohort 3). Safety and tolerability data collected through Day 35 in each preceding cohort are reviewed before initiating dosing in the next higher-dose cohort.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Incidence of Treatment-Emergent Adverse Events
Number and percentage of subjects experiencing any treatment-emergent adverse event (TEAE) following multiple intravenous administrations of KINE-101 or placebo. Safety assessments will also include concomitant medications, physical examinations, local injection site reactions, and vital signs.
Time frame: From Day 1 to Day 35 (End of Study visit)
Maximum plasma concentration (Cmax)
Maximum plasma concentration (Cmax) of KINE-101 following single and multiple doses.
Time frame: From Day 1 (pre-dose) through Day 7 post-dose
Area under the plasma concentration-time curve (AUC)
Area under the plasma concentration-time curve (AUC) of KINE-101 following single and multiple doses.
Time frame: From Day 1 (pre-dose) through Day 7 post-dose
Terminal half life (t½)
Terminal half life (t½) of KINE-101 following single and multiple doses.
Time frame: From Day 1 (pre-dose) through Day 7 post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.